IP Library Granted Patent US 11,185,478
Granted Patent B2
US 11,185,478 · App. 16/577,212 · Granted Nov 30, 2021

Buffered microencapsulated compositions and methods

Inventors: Mark A. Latta (Omaha, NE); Stephen M. Gross (Omaha, NE); William A. McHale (Collegeville, PA)
Assignee: Premier Dental Products Company
A61K8/11A61K6/20A61K6/69A61K6/71A61K8/19A61K8/21A61K8/24A61K8/64A61K8/87A61K9/0056A61K9/5031A61K9/5089A61K33/06A61K33/16A61K33/44A61K47/02A61Q3/02A61Q5/02A61Q5/06A61Q5/12A61Q11/00A61Q19/00A61K2800/412
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,185,478
App. No.
16/577,212
Granted
Nov 30, 2021
Kind
B2
Abstract

A microcapsule composition comprising at least one polymer substantially disposed as a semipermeable shell around a buffered solution and at least one therapeutic agent, wherein the therapeutic agent permeates the shell, and wherein the composition is suitable for delivery to a mammal. This invention also provides related compositions, products and methods.

Claims (16)

1. A product for increasing the bone mass of a mammal, comprising a microcapsule composition comprising a polymer substantially disposed as a semipermeable shell around a buffered solution, said microcapsule composition comprising at least a first subset of microcapsules and a second subset of microcapsules, wherein the first subset of microcapsules comprises a first therapeutic agent and wherein the second subset of microcapsules comprises a second therapeutic agent, wherein the first therapeutic agent and the second therapeutic agent each permeate their respective shells, and wherein the composition is suitable for delivery to a mammal.

2. The product of claim 1 wherein the buffered solution is an aqueous solution.

3. The product of claim 1 wherein the buffered solution is a nonaqueous solution.

4. The product of claim 1 wherein the second therapeutic agent is selected from the group consisting of: an antimicrobial agent, a tooth whitening agent, an antibiotic, an anticoagulant, a remineralizing agent, an anticaries agent, a desensitizing agent, and an anti-inflammatory agent.

5. The product of claim 1 wherein the molecular weight of the polymer is from about 1,000 g/mole to about 50,000 g/mole.

6. The product of claim 1 wherein the polymer is cross-linked.

7. The product of claim 1 wherein the microcapsule has a diameter of from about 1 micron to about 3 mm.

8. The product of claim 1 in the form of a paste, a gel, a foam, a rinse, a dentifrice, a tooth whitening product, a breath freshener, an artificial saliva system, a varnish, a desensitizer, a dental restorative, a composite, an adhesive, a cement, a bioactive glass, a glass ionomer, a compomer, a giomer, a resin, a denture tooth, a denture base material, a root canal filler, a sealer, a chewing gum, a dental implant tissue regeneration material, a pulp capping material, and a filling restorative.

9. The product of claim 1 further comprising an additive selected from the group consisting of preservatives, antitartar agents, anticalculous agents, antimicrobial agents, flavorings, sweeteners, and dyes.

10. The product of claim 1 wherein the second therapeutic agent causes tissue mineralization.

11. The product of claim 1 wherein the first subset of microcapsules has a therapeutic agent release profile that differs from the therapeutic agent release profile of the second subset of microcapsules.

12. A pharmaceutical composition comprising the product of claim 1 and a pharmaceutically acceptable carrier.

13. A food material composition comprising a microcapsule composition comprising an amphiphilic polyurethane polymer substantially disposed as a semipermeable shell around a buffered solution, said microcapsule composition comprising at least a first subset of microcapsules and a second subset of microcapsules, wherein the first subset of microcapsules comprises a bone mass increasing therapeutic agent and wherein the second subset of microcapsules comprises a second therapeutic agent, wherein the therapeutic agents permeate the shell, and wherein the composition is suitable for delivery to a mammal.

14. The composition of claim 13 further comprising an additive selected from the group consisting of preservatives, antitartar agents, anticalculous agents, antimicrobial agents, flavorings, sweeteners, and dyes.

15. The composition of claim 13 wherein the second therapeutic agent causes tissue mineralization.

16. The composition of claim 13 wherein the first subset of microcapsules has a therapeutic agent release profile that differs from the therapeutic agent release profile of the second subset of microcapsules.

Assignments (3)
SECURITY INTEREST Recorded Mar 27, 2025
From: PREMIER DENTAL PRODUCTS COMPANY, LLC
To: FIDELITY DIRECT LENDING LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 070650/0397 →
ENTITY CONVERSION Recorded Mar 17, 2025
From: PREMIER DENTAL PRODUCTS COMPANY
To: PREMIER DENTAL PRODUCTS COMPANY, LLC
Reel/Frame 070537/0105 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2020
From: LATTA, MARK A.; GROSS, STEPHEN M.; MCHALE, WILLIAM A.
To: PREMIER DENTAL PRODUCTS COMPANY
Reel/Frame 053034/0393 →
Continuity (5)
Division 15791554 · Oct 24, 2017
Division 13619128 · Sep 14, 2012
Continuation In Part 12768696 · Apr 27, 2010
Provisional Application 61172939 · Apr 27, 2009
Related Publication 20200009028A1 · Jan 9, 2020